Literature DB >> 10697267

Androgen receptors: a marker to increase sensitivity for identifying breast cancer in skin metastasis of unknown primary site.

I B Bayer-Garner1, B Smoller.   

Abstract

Metastatic lesions to the skin may present a dilemma in the identification of the primary site. Breast carcinoma, metastatic to the skin, that is negative for estrogen receptors (ERs) and/or progesterone receptors (PRs) may be mimicked by a number of other metastatic lesions. In the present study, 16 formalin-fixed and paraffin-embedded infiltrating ductal carcinomas metastatic to the skin, which were ER-/PR-, ER-/PR+, or ER+/PR-; 5 metastatic lesions to the skin from primary lesions other than breast cancer; and 5 eccrine tumors were examined for immunoreactivity to the androgen receptor. The majority of the metastatic breast lesions (82%) exhibited immunopositivity for androgen receptor, whereas the metastatic skin lesions from primary lesions other than breast cancer and the eccrine tumors were immunonegative. Thus, androgen receptor immunohistochemistry could serve as a marker to increase sensitivity for identifying breast cancer in skin metastasis of unknown primary sites.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10697267     DOI: 10.1038/modpathol.3880021

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  11 in total

1.  The war on cancer: a report from the front lines.

Authors:  Gavin Melmed
Journal:  Proc (Bayl Univ Med Cent)       Date:  2006-10

2.  Combined profile of the tandem repeats CAG, TA and CA of the androgen and estrogen receptor genes in breast cancer.

Authors:  Andrei Anghel; Marius Raica; Catalin Marian; Sorin Ursoniu; Oana Mitrasca
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-22       Impact factor: 4.553

3.  Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers.

Authors:  Donata Micello; Alessandro Marando; Nora Sahnane; Cristina Riva; Carlo Capella; Fausto Sessa
Journal:  Virchows Arch       Date:  2010-08-31       Impact factor: 4.064

4.  Prolactin/Stat5 and androgen R1881 coactivate carboxypeptidase-D gene in breast cancer cells.

Authors:  Samir Koirala; Lynn N Thomas; Catherine K L Too
Journal:  Mol Endocrinol       Date:  2014-01-16

5.  Maspin expression in epithelial skin tumours: an immunohistochemical study.

Authors:  Asmaa Gaber Abdou; Alaa Hassan Maraee; Mohamed Abd El-Monaem Shoeib; Amany Mohamed Abo Saida
Journal:  J Cutan Aesthet Surg       Date:  2011-05

6.  Androgen receptor expression in metastatic adenocarcinoma in females favors a breast primary.

Authors:  Vinod B Shidham; Richard A Komorowski; Jinobya K Machhi
Journal:  Diagn Pathol       Date:  2006-10-04       Impact factor: 2.644

7.  Androgen receptor expresion in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors.

Authors:  Luis O Gonzalez; Maria D Corte; Julio Vazquez; Sara Junquera; Rosario Sanchez; Ana C Alvarez; Juan C Rodriguez; Maria L Lamelas; Francisco J Vizoso
Journal:  BMC Cancer       Date:  2008-05-28       Impact factor: 4.430

8.  Abnormal mammary gland development and growth retardation in female mice and MCF7 breast cancer cells lacking androgen receptor.

Authors:  Shuyuan Yeh; Yueh-Chiang Hu; Peng-Hui Wang; Chao Xie; Qingquan Xu; Meng-Yin Tsai; Zhihong Dong; Ruey-Sheng Wang; Ting-Hein Lee; Chawnshang Chang
Journal:  J Exp Med       Date:  2003-12-15       Impact factor: 14.307

Review 9.  The role of androgens and polymorphisms in the androgen receptor in the epidemiology of breast cancer.

Authors:  Elizabeth O Lillie; Leslie Bernstein; Giske Ursin
Journal:  Breast Cancer Res       Date:  2003-04-02       Impact factor: 6.466

10.  Long term use of bevacizumab in the treatment of triple negative breast cancer with giant tumor in chest wall: A case report.

Authors:  Xinyu Gui; Huiping Li; Guohong Song; Bin Shao; Hanfang Jiang
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.